[go: up one dir, main page]

WO2007135568A3 - PROCÉDÉ DESTINÉ À PRÉDIRE LA FACULTÉ DE RÉPONDRE À DES AGENTS BLOQUANT LE TNFα - Google Patents

PROCÉDÉ DESTINÉ À PRÉDIRE LA FACULTÉ DE RÉPONDRE À DES AGENTS BLOQUANT LE TNFα Download PDF

Info

Publication number
WO2007135568A3
WO2007135568A3 PCT/IB2007/002373 IB2007002373W WO2007135568A3 WO 2007135568 A3 WO2007135568 A3 WO 2007135568A3 IB 2007002373 W IB2007002373 W IB 2007002373W WO 2007135568 A3 WO2007135568 A3 WO 2007135568A3
Authority
WO
WIPO (PCT)
Prior art keywords
blocking agents
tnfα blocking
predicting responsiveness
genes
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002373
Other languages
English (en)
Other versions
WO2007135568A2 (fr
Inventor
Jean-Philippe Salier
Maryvonne Daveau
Anne-Christin Gauthier-Jauneau
Olivier Vittecoq
Loet Xavier Le
Alain Daragon
Othmane Mejjad
Thierry Lequerre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to ES07789647T priority Critical patent/ES2375865T3/es
Priority to EP07789647A priority patent/EP2019872B1/fr
Priority to AT07789647T priority patent/ATE530670T1/de
Priority to CA002652087A priority patent/CA2652087A1/fr
Priority to US12/300,847 priority patent/US7985549B2/en
Priority to DK07789647.0T priority patent/DK2019872T3/da
Publication of WO2007135568A2 publication Critical patent/WO2007135568A2/fr
Publication of WO2007135568A3 publication Critical patent/WO2007135568A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials Using Thermal Means (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé in vitro destiné à prédire si un patient est susceptible de répondre à un traitement par un agent bloquant le TNFα. Le procédé consiste à déterminer le niveau d'expression de huit gènes dans un échantillon biologique dudit patient, lesdits gènes étant les EPS15, HLA-DPB1, AKAP9, RASGRP3, MTCBP-1, PTNP12, MRPL22 et RPS28. L'invention concerne en outre une puce à ADN permettant la mise en œuvre dudit procédé.
PCT/IB2007/002373 2006-05-16 2007-05-15 PROCÉDÉ DESTINÉ À PRÉDIRE LA FACULTÉ DE RÉPONDRE À DES AGENTS BLOQUANT LE TNFα Ceased WO2007135568A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES07789647T ES2375865T3 (es) 2006-05-16 2007-05-15 Método para predecir la respuesta a agentes bloqueadores del tnf.
EP07789647A EP2019872B1 (fr) 2006-05-16 2007-05-15 Méthode de prédiction de la réponse aux agents de blocage de tnf
AT07789647T ATE530670T1 (de) 2006-05-16 2007-05-15 Verfahren zur vorhersage der ansprechempfindlichkeit auf tnf-blocker
CA002652087A CA2652087A1 (fr) 2006-05-16 2007-05-15 Procede destine a predire la faculte de repondre a des agents bloquant le tnfa
US12/300,847 US7985549B2 (en) 2006-05-16 2007-05-15 Method for predicting responsiveness to TNFα blocking agents
DK07789647.0T DK2019872T3 (da) 2006-05-16 2007-05-15 Fremgangsmåde til forudsigelse af modtageligheden over for TNF-blokkere

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06290789.4 2006-05-16
EP06290789A EP1857559A1 (fr) 2006-05-16 2006-05-16 Méthode de prédiction de la réponse aux agents de blocage de TNF aplha

Publications (2)

Publication Number Publication Date
WO2007135568A2 WO2007135568A2 (fr) 2007-11-29
WO2007135568A3 true WO2007135568A3 (fr) 2008-02-28

Family

ID=36764554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002373 Ceased WO2007135568A2 (fr) 2006-05-16 2007-05-15 PROCÉDÉ DESTINÉ À PRÉDIRE LA FACULTÉ DE RÉPONDRE À DES AGENTS BLOQUANT LE TNFα

Country Status (7)

Country Link
US (1) US7985549B2 (fr)
EP (2) EP1857559A1 (fr)
AT (1) ATE530670T1 (fr)
CA (1) CA2652087A1 (fr)
DK (1) DK2019872T3 (fr)
ES (1) ES2375865T3 (fr)
WO (1) WO2007135568A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100037590A (ko) * 2007-06-08 2010-04-09 바이오겐 아이덱 엠에이 인코포레이티드 항 ｔｎｆ 반응 또는 무반응을 예측하기 위한 바이오마커
WO2009117791A2 (fr) * 2008-03-28 2009-10-01 Katholieke Universiteit Leuven Signatures génétiques des muqueuses
EP2288732B1 (fr) * 2008-06-12 2013-10-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour prévoir la réponse à un traitement à l'anakinra
ES2335381B1 (es) * 2008-09-24 2011-02-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
EP2192197A1 (fr) * 2008-11-27 2010-06-02 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Prévision de la réponse clinique à un traitement avec un antagoniste du tnf soluble ou le tnf, ou un agoniste du récepteur du tnf
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
RS61082B1 (sr) 2010-02-26 2020-12-31 Novo Nordisk As Stabilno antitelo koje sadrži kompozicije
US20130095099A1 (en) * 2010-03-24 2013-04-18 Tc Land Expression Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
JP6181646B2 (ja) * 2011-07-06 2017-08-16 ネステク ソシエテ アノニム Ｔｎｆアルファによる生物学的治療に対する中和自己抗体の検出のためのアッセイ
CA2864133A1 (fr) 2012-02-10 2013-08-15 Novo Nordisk A/S Methodes liees au traitement des maladies inflammatoires
HU230680B1 (hu) * 2012-10-19 2017-08-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Diagnosztikai eljárás
US20140255393A1 (en) * 2013-02-28 2014-09-11 Nodality, Inc. Compositions and methods for autoimmune disease
EP3884276A2 (fr) * 2018-11-23 2021-09-29 Katholieke Universiteit Leuven Prédiction d'une réponse à un traitement dans une maladie intestinale inflammatoire
IL309552A (en) * 2021-06-22 2024-02-01 Scipher Medicine Corp Methods and systems for monitoring treatment and experimental design

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196799A1 (en) * 1997-10-30 2005-09-08 Cold Spring Harbor Laboratory Use of representations of DNA for genetic analysis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US196799A (en) 1877-11-06 Improvement in washing-machines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196799A1 (en) * 1997-10-30 2005-09-08 Cold Spring Harbor Laboratory Use of representations of DNA for genetic analysis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOR THE ATTRACT STUDY GROUP MAINI R ET AL: "Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 354, no. 9194, 4 December 1999 (1999-12-04), pages 1932 - 1939, XP004827470, ISSN: 0140-6736 *
T. LEQUERRÉ ET AL: "Gene expression profiling in PBMCs as a tool for prediction of infliximab responsiveness in rheumatoid arthritis.", ARTHRITIS & RHEUMATISM, vol. 50, 2004, pages S398, XP008067698 *
T. LEQUERRÉ ET AL: "Prediction of infliximab responsiveness in rheumatoid arthritis from gene profiling in PBMCs, but not with autoantibodies (autoab), metalloproteinases and bone markers parameters in sera of patients.", ARTHRITIS & RHEUMATISM, vol. 52, no. 9S, September 2005 (2005-09-01), pages S569 - S570, XP002394784 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Also Published As

Publication number Publication date
US7985549B2 (en) 2011-07-26
US20090252740A1 (en) 2009-10-08
ES2375865T3 (es) 2012-03-07
EP1857559A1 (fr) 2007-11-21
ATE530670T1 (de) 2011-11-15
EP2019872A2 (fr) 2009-02-04
EP2019872B1 (fr) 2011-10-26
CA2652087A1 (fr) 2007-11-29
WO2007135568A2 (fr) 2007-11-29
DK2019872T3 (da) 2012-01-16

Similar Documents

Publication Publication Date Title
WO2007135568A3 (fr) PROCÉDÉ DESTINÉ À PRÉDIRE LA FACULTÉ DE RÉPONDRE À DES AGENTS BLOQUANT LE TNFα
WO2008109423A8 (fr) Dosage multigène pour prédire les résultats de traitement concernant un individu atteint de glioblastome
DE602005009702D1 (de) Esr1 und gebärmutterhalskrebs
WO2008115419A3 (fr) Marqueurs d'expression de gène pour la prévision de la réponse d'un patient à une chimiothérapie
WO2009074983A3 (fr) Analyse permettant de détecter les acides nucléiques libres en circulation
WO2008113111A8 (fr) Dosage de l'expression génétique
ATE406463T1 (de) Methode zur krebsdiagnose mittels nachweis von dna und rna im kreislauf
EP2032714A4 (fr) Amorces d'oligonucléotides chimiquement modifiées pour l'amplification de l'acide nucléique
NZ593226A (en) Gene expression markers (efnb2) for colorectal cancer prognosis
WO2007103558A3 (fr) Transfert d'energie hybride pour la detection d'acide nucleique
WO2004053105A3 (fr) Detection de snp directe avec adn non amplifie
WO2007035684A3 (fr) Procede de detection quantitative de molecules d'arn courts
WO2007067968A3 (fr) Effets d'inhibiteurs de fgfr3 sur la transcription genetique
WO2007133682A3 (fr) Procédés de détection à 100 % de l'identité d'une séquence pour divers génomes
WO2006028601A3 (fr) Technique permettant de distinguer un staphylocoque dore resistant a la methicilline d'un staphylocoque dore sensible a la methicilline dans une culture mixte
WO2008073177A3 (fr) Profils d'expression génique et protéique associés à l'efficacité thérapeutique de l'irinotécan
EP2055789A4 (fr) Jeu d'amorces pour l'amplification du gène cyp2c19, réactif pour l'amplification du gène cyp2c19 comprenant ledit jeu d'amorces et utilisation du réactif
WO2009097511A3 (fr) Enrichissement en deux étapes d'adn fœtal acellulaire dans du plasma maternel
DE502008002136D1 (de) Kontrollgene zur normalisierung von genexpressionsanalysedaten
WO2006077102A3 (fr) Methode de detection et matieres associees
WO2006037462A3 (fr) Marqueurs du cancer
ATE541056T1 (de) Verwendung von dna-polymerasen wie exoribonukleasen
WO2010099378A3 (fr) Dosage de détection de l'acide nucléique du parvovirus humain
WO2007021250A3 (fr) Procede et/ou dispositif de conception d'oligonucleotides et/ou de detection d'acides nucleiques
DK1815013T3 (da) Sammensætning til at amplificere nucleinsyrer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789647

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2652087

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12300847

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007789647

Country of ref document: EP